Abstract
The relationship between surface expression of the interleukin-2 receptor (IL-2R) and release of the soluble form of the receptor (sIL-2Rα or sCD25) was investigated with peripheral blood mononuclear cells (PBMCs) from individuals with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). The spontaneous release of sCD25 was significantly increased in PBMCs from RA patients and decreased in cells from SLE patients, compared with normal controls. However, the extent of sCD25 release from phytohaemagglutinin (PHA)-stimulated PBMCs did not differ between RA or SLE patients and normal controls. The serum concentration of sCD25 was significantly increased in SLE or RA patients compared with the normal controls. Whereas the surface expression of CD25 by unstimulated PBMCs did not differ among the three groups of subjects, this parameter was significantly reduced for PHA-stimulated PBMCs from RA patients relative to those from normal controls. The surface expression of CD25 showed a positive correlation with sCD25 release for PBMMCs from SLE patients under either basal or stimulated conditions. No such relation was apparent for cells from RA patients. The surface expression of IL-2Rβ (CD122) under basal or stimulated conditions was significantly reduced in PBMCs from RA or SLE patients, compared with cells from normal controls. Thus, the increased concentration of sCD25 in the serum of individuals with these autoimmune rheumatic diseases may result from two different mechanisms: an increase in the spontaneous release of sCD25 in RA, and reduced clearance of this protein in SLE.
Similar content being viewed by others
References
Rubin LA, Kurman CC, fritz ME, Biddison WE, Boutin B, Yarchoan R, et al. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985;135:3172–7.
Wolf RE, Brelsford WG. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum 1988;31:729–35.
Ward MM, Dooley MA, Christenson VD, Pisetsky DS. The relationship between soluble interleukin 2 receptor levels and anti-double stranded DNA antibody levels in patients with systemic lupus erythematosus. J Rheumatol 1991;18:235–40.
Plater-zyberk C, Rockett KA, Maini RN. Spontaneous recovery of the decreased expression in vitro of interleukin-2 receptors in rheumatoid arthritis. Clin Exp Immunol 1988;73:93–7.
Keystone EC, Snow KM, Bombardier C, Chang C-H, Nelson DL, Rubin LA. Elevated soluble interleukin-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. Arthritis Rheum 1988;31:844–9.
Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska K Jr. Soluble interleukin-2 receptors in patients with systemic sclerosis. Arthritis Rheum 1990;33:375–80.
Wolf RE, Baethge BA. Interleukin-1α, interleukin-2, and soluble interleukin-2 receptors in polymyositis. Arthritis Rheum 1990;33:1007–14.
Giordano C, Galluzzo A, Marco A, Panto F, Amato MP, Caruso C, et al. Increased soluble interleukin-2 receptor levels in the sera of type 1 diabetic patients. Diabetes Res 1988;8:135–8.
Robb RJ, Kutny RM. Structure-function relationships for the IL-2 receptor system: IV. Analysis of the sequence and ligand-binding properties of soluble Tac protein. J Immunol 1987;139:855–62.
Treiger BF, Leonard WJ, Svetlik P, Rubin LA, Nelson DL, Greene WC. A secreted form of the human interleukin-2 receptor encoded by an ‘anchor minus’ cDNA. J Immunol 1986;136:4099–105.
Laut J, Senitzer D, Petrucci R, Sablay LB, Barland P, Glicklich D. Sotuble interleukin-2 receptor levels in lupus nephritis. Clin Nephrol 1992;38:179–84.
Pizzolo G, Chilosi M, Semenzato G. Annotation: The soluble interleukin-2 receptor in haematological disorders. Br J Haematol 1987;67:377–80.
Arend WP. Inhibiting the effects of cytokines in human diseases. Adv Intern Med 1995;40:365–94.
Muller-Newen G, Kohne C, Heinrich PC. Soluble receptors for cytokines and growth factors. Int Arch Allergy Immunol 1996;11:99–106.
Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J 1991;5:2567–74.
Heaney ML, Golde DW. Soluble cytokine receptors. Blood 1996;87:847–57.
Campen DH, Horwitz DA, Quismorio FP Jr, Ehresmann GR, Martin WJ. Serum levels of interleukin-2 receptor and activation of rheumatic diseases characterized by immune system activation. Arthritis Rheum 1988;31:1358–64.
Carpenter AB, Eisenbeis CH Jr, Carrabis S, Brown MC, Ip SH. Soluble interleukin-2 receptor: elevated levels in serum and synovial fluid of patients with rheumatoid arthritis. J Clin Lab Analysis 1990;4:130–4.
Manoussakis MN, Papadopoulos GK, Drosos AA, Moutsopoulos HM. Soluble interleukin-2 receptor molecules in the serum of patients with autoimmune diseases. Clin Immunol Immunopathol 1989;50:321–32.
Chan EY-T, Lau C-S, Zola H. Expression of IL-2R, IL-4R, IL-6R on peripheral blood lymphocytes in systemic lupus erythematosus and correlation with disease activity: a prospective study. J Clin Pathol 1996;49:660–3.
Shahabuddin S. Expression and release of IL-2 receptor and production of IL-2 by activated T lymphocyte subsets. J Clin Lab Immunol 1991;36:27–32.
Symons JA, Wood NC, Di Giovone FS, Duff GW. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol 1988;141:2612–18.
Junghans, R.P., Waldmann, T.A. Metabolism of Tac (IL2Rα): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J Exp Med 1996;183:1587–602.
Ishida H, Kumagai S, Umehara H, Sano H, Tagaya Y, Yodoi J, et al. Impaired expression of high affinity interleukin 2 receptor on activated lymphocytes from patients with systemic lupus erythematosus. J Immunol 1987;139:1070–4.
Tanaka T, Saiki O, Negoro S, Igarashi T, Kuritani T, Hara H, et al. Decreased expression of interleukin-2 binding molecules (p70/75) in T cells from patients with systemic lupus erythematosus. Arthritis Rheum 1989;32:552–9.
Alcocer-Varela J, Alarcon-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982;69:1388–92.
Kondo N, Kondo S, Shimizu A, Honjo T, Hamuro J. A soluble ‘anchor minus’ interleukin 2 receptor suppresses in vitro interleukin 2-mediated immune responses. Immunol Lett 1988;19:289–308.
Jacques Y, Le Mauff B, Boeffard F, Godard A, Soulillou J-P. A soluble interleukin 2 receptor produced by a normal alloreactive human T cell clone binds interleukin 2 with low affinity. J Immunol 1987;139:2308–16.
Miossec P, Elhamiani M, Edmonds-Alt X, Sany J, Hirn M. Functional studies of soluble low-affinity interleukin-2 receptors in rheumatoid synovial fluid. Arthritis Rheum 1990;33:1688–93.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Itoh, M., Goto, Y., Ohta, Y. et al. Relations between surface expression of the interleukin-2 receptor and release of the soluble form of the receptor in cultured mononuclear cells from patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Rheumatol 17, 26–30 (1998). https://doi.org/10.1007/BF01450954
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01450954